Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (NASDAQ: EVFM) reported its 2020 financial results, highlighting its U.S. launch of Phexxi, a non-hormonal birth control method. The 'Get Phexxi' campaign generated over 115 million views, resulting in a 362% increase in direct searches. Despite this, net product sales for Q4 were approximately $170,000, with a net loss of $40.6 million. For the year, net sales totaled around $450,000, with a net loss of $142.3 million. Evofem secured a $25 million strategic investment to fund clinical trials and boost market access. The company continues to focus on addressing unmet medical needs for women.
Evofem Biosciences (NASDAQ: EVFM) announced its presentation at the H.C. Wainwright Global Life Sciences Conference on February 23, 2021. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, a non-hormonal birth control method. The presentation will be available for on-demand listening starting March 9, 2021, at 7:00 a.m. ET on their website. Additionally, on Valentine's Day, Evofem launched a DTC campaign called 'Get Phexxi' to enhance awareness of its product.
Phexxi® is the first and only hormone-free prescription vaginal gel in the U.S. for pregnancy prevention.
Evofem Biosciences, Inc. (NASDAQ: EVFM) is set to hold a webcast and conference call on March 4, 2021, at 4:30 p.m. ET, to discuss its financial results and business highlights for the fourth quarter and full year ended December 31, 2020. Investors can access the live webcast through the Company’s website or by dialing (866) 503-5561 for U.S. callers. The conference ID is 9928997. Evofem focuses on innovative women’s health solutions, including the hormone-free contraceptive Phexxi®. More details can be found at the company’s website.
Evofem Biosciences, Inc. (NASDAQ: EVFM) has launched its "Get Phexxi" direct-to-consumer campaign to raise awareness about Phexxi®, a non-hormonal birth control method approved by the FDA in May 2020. The campaign addresses the 21 million women in the U.S. at risk for pregnancy who are not using hormonal contraception. The initiative, launched on Valentine's Day, aims to educate women on Phexxi's benefits as an on-demand contraceptive. The campaign includes a national TV commercial and a targeted digital marketing strategy, responding to frustrations expressed by women regarding existing birth control methods.
Evofem Biosciences (NASDAQ: EVFM) and NCODA have partnered to enhance awareness of Phexxi®, a non-hormonal contraceptive, among female cancer patients. This collaboration, initiated on World Cancer Day, aims to provide resources and educational materials for oncology teams to support patients in selecting the best contraceptive options. With over 800,000 new cancer cases reported annually in women in the U.S., the need for non-hormonal options like Phexxi, approved in May 2020, is critical as many cancer treatments necessitate birth control use.
Summary not available.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced its participation in the Medicaid National Drug Rebate Program, effective January 1, 2021. This agreement allows access to Phexxi® (lactic acid, citric acid, and potassium bitartrate) for Medicaid recipients, ensuring equitable contraceptive options for women. Approximately 69.8 million individuals are covered by Medicaid in the U.S., with around 25 million being adult women. The Medicaid Drug Rebate Program aims to reduce costs for outpatient prescription drugs for Medicaid patients, with broad participation from manufacturers.
Evofem Biosciences (NASDAQ: EVFM) announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference on December 21, 2020. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, the first FDA-approved hormone-free contraceptive vaginal gel, and provide updates on the ongoing EVOGUARD Phase 3 trial. This trial evaluates EVO100 in preventing chlamydia and gonorrhea. The presentation will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern on the company's website under the Events and Presentations tab.
Evofem Biosciences (NASDAQ: EVFM) announced progress in its Phase 3 trial, EVOGUARD, evaluating EVO100 for preventing chlamydia and gonorrhea. Launched in October 2020, enrollment exceeded targets amid COVID-19 challenges. Inbound interest from study centers doubled expectations, with one-third operational by year-end. If successful, EVO100 could offer a new preventive method, following the positive AMPREVENCE trial, showing a 50% reduction in chlamydia and 78% for gonorrhea. EVO100 holds Fast Track and QIDP designations from the FDA.
Evofem Biosciences (NASDAQ: EVFM) announced the listing of two U.S. patents for its contraceptive product, Phexxi®, in the FDA's Orange Book. Phexxi, the first FDA-approved non-hormonal vaginal gel for contraception, was approved in May 2020. The listed patents include the '855 patent, which covers contraception methods and expires in March 2033, and the '276 patent, a composition patent expiring in March 2026. CEO Saundra Pelletier highlighted this listing as a crucial step in expanding their patent portfolio and securing the product's market position.